Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1)
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tirzepatide as Monotherapy Improved Markers of Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes (SURPASS-1)
Authors
Keywords
-
Journal
Journal of the Endocrine Society
Volume 7, Issue 5, Pages -
Publisher
The Endocrine Society
Online
2023-04-23
DOI
10.1210/jendso/bvad056
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
- (2022) Dominik Dahl et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 337-OR: Tirzepatide Improved Markers of Islet-Cell Function (Fasting Glucagon and HOMA2-B) and Insulin Sensitivity (Fasting Insulin and HOMA2-IR) Compared with Semaglutide in People with Type 2 Diabetes
- (2022) KATELYN BROWN et al. DIABETES
- Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
- (2022) Tim Heise et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
- (2021) Stefano Del Prato et al. LANCET
- How May GIP Enhance the Therapeutic Efficacy of GLP-1?
- (2020) Ricardo J. Samms et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
- (2020) Melissa K Thomas et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Obesity dysregulates fasting-induced changes in glucagon secretion
- (2019) Jennifer H Stern et al. JOURNAL OF ENDOCRINOLOGY
- Insulin-Like Growth Factor Binding Protein 2 (IGFBP-2) and the Risk of Developing Type 2 Diabetes
- (2018) Clemens Wittenbecher et al. DIABETES
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- Insulin action and resistance in obesity and type 2 diabetes
- (2017) Michael P Czech NATURE MEDICINE
- Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model
- (2008) R E Weaver et al. INTERNATIONAL JOURNAL OF OBESITY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search